TP53 and cervical carcinoma: Promisingly, a clinical trial has compared the use of p53 expressing adenoviral vector in cervical cancer patients and found that when used in combination as neoadjuvant chemotherapy, tumour regression almost comparable to that in a cisplatin, vinblastine, and bleomycin (PVB) treatment group was observed .41